June 1, 2005

CLEP OF NEW YORK GRANTS AMBRY GENETICS CERTIFICATION STATUS

IRVINE, CA (June 1, 2005) – AMBRY GENETICS announced it has met all quality standards to accept clinical specimens obtained in New York State for Cystic Fibrosis genetic testing. The approval was granted by the Clinical Laboratory Evaluation Program (CLEP) of the Wadsworth Center. In 1965, New York became the first state in the nation to initiate a certification and licensing program for a limited number of clinical laboratories operating within the state in selected areas of patient testing.

CLEP monitors the overall quality of testing conducted by permit-holding clinical facilities and provides guidelines, quality control standards and procedures to be used. The program seeks to ensure the accuracy and reliability of results of laboratory tests on specimens obtained within the state through on-site inspections, proficiency testing and evaluation of the qualifications of personnel. CLEP currently issues permits to approximately 1,000 laboratories and 600 patient service centers in New York State on an annual basis.

AMBRY GENETICS

Ambry Genetics is a worldwide leader in specialized genetic testing. The proprietary Ambry Test™ combines scanning and sequencing technologies to analyze a gene’s entire coding region plus surrounding critical introns. Capable of identifying approximately 99% of all disease-causing mutations of the CFTR gene, the company’s reputable Cystic Fibrosis test has an unrivaled detection rate across all ethnic groups. The Company also created the world’s first and only comprehensive genetic test for three principal genes (PRSS1, SPINK1 and CFTR) associated with Chronic and Hereditary Pancreatitis. Ambry Genetics is striving to lessen inherited diseases and is committed to providing the basis for more effective treatments and targeted prevention through molecular understanding. Headquartered in Irvine, California, the Company’s advancements are providing precise, cost effective methods to aid in disease definition and early, more accurate diagnosis. Several academic and pharmaceutical research projects are underway, including expanded population statistical analysis and the development of assays for other genes. Ambry Genetics is a CAP accredited laboratory. Website: www.ambrygen.com.